Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients and clinical practice guidelines

Imagem de Miniatura
Arquivos
art_ARIYAWARDANA_Systematic_review_of_antiinflammatory_agents_for_the_management_2019.PDF (451.58 KB)
Citações na Scopus
78
Tipo de produção
article
Data de publicação
2019
Editora
SPRINGER
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
ARIYAWARDANA, Anura
CHENG, Karis Kin Fong
KANDWAL, Abhishek
AL-AZRI, Abdul Rahman
GALITI, Dimitra
CHIANG, Karen
VADDI, Anusha
RANNA, Vinisha
NICOLATOU-GALITIS, Ourania
Autor de Grupo de pesquisa
MASCC ISOO
Editores
Coordenadores
Organizadores
Citação
SUPPORTIVE CARE IN CANCER, v.27, n.10, p.3985-3995, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose The aim of this systematic review was to update the clinical practice guidelines for the use of anti-inflammatory agents in the prevention and/or treatment of oral mucositis. Methods A systematic review was conducted by the Multinational Association of Supportive Care in Cancer/ International Society of Oral Oncology (MASCC/ISOO) subcommittee on mucositis guideline update. The body of evidence for each intervention, in each cancer treatment setting, was assigned an evidence level. The findings were added to the database used to develop the clinical practice guidelines published in 2014. Based on the evidence level, one of the following three guideline determinations was possible: recommendation, suggestion, and no guidelines. Results A total of 11 new papers across five interventions were examined. The recommendation for the use of benzydamine mouthwash for the prevention of radiotherapy-induced mucositis remained unchanged. New suggestion for the use of the same for prevention of mucositis associated with chemoradiotherapy was made. No guideline was possible for any other anti-inflammatory agents due to inadequate and/or conflicting evidence. Conclusions Of the anti-inflammatory agents studied for oral mucositis, the evidence supports the use of benzydamine mouthwash in the specific populations listed above. Additional well-designed research is needed on other (class of agents) interventions and in other cancer treatment settings.
Palavras-chave
Oral mucositis, Cancer, Management, Anti-inflammatory agents, Intervention, Guidelines, Radiotherapy, Chemotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/34131
Referências
  1. Barasch A, 2006, SUPPORT CARE CANCER, V14, P528, DOI 10.1007/s00520-006-0066-1
  2. Barkokebas A, 2015, J ORAL PATHOL MED, V44, P746, DOI 10.1111/jop.12282
  3. Chaitanya B, 2017, ORAL ONCOL, V72, P179, DOI 10.1016/j.oraloncology.2017.07.024
  4. Chang JE, 2015, CAN J ANESTH, V62, P1097, DOI 10.1007/s12630-015-0432-x
  5. Cheng K K F, 2004, Eur J Oncol Nurs, V8, P341, DOI 10.1016/j.ejon.2004.04.002
  6. Cheng KKF, 2006, CANCER NURS, V29, P423, DOI 10.1097/00002820-200609000-00012
  7. Cheng KKF, 2004, EUR J CANCER, V40, P1208, DOI 10.1016/j.ejca.2003.10.023
  8. Cheng KKF, 2003, CANCER NURS, V26, P476
  9. Chitapanarux I, 2018, SUPPORT CARE CANCER, V26, P879, DOI 10.1007/s00520-017-3904-4
  10. DuenasGonzalez A, 1996, BONE MARROW TRANSPL, V17, P809
  11. EPSTEIN JB, 1986, ORAL SURG ORAL MED O, V62, P145, DOI 10.1016/0030-4220(86)90035-6
  12. EPSTEIN JB, 1989, INT J RADIAT ONCOL, V16, P1571, DOI 10.1016/0360-3016(89)90964-4
  13. Epstein JB, 2001, CANCER, V92, P875, DOI 10.1002/1097-0142(20010815)92:4<875::AID-CNCR1396>3.0.CO;2-1
  14. Erdem O, 2014, HOLIST NURS PRACT, V28, P242, DOI 10.1097/HNP.0000000000000033
  15. Hadjieva T, 2014, SUPPORT CARE CANCER, V22, P1557, DOI 10.1007/s00520-014-2117-3
  16. Hadorn DC, 1996, J CLIN EPIDEMIOL, V49, P749, DOI 10.1016/0895-4356(96)00019-4
  17. Hanson WR, 1997, ADV EXP MED BIOL, V400, P811
  18. HAYNES DR, 1992, IMMUNOLOGY, V76, P251
  19. Jayachandran Sadaksharam, 2012, Indian J Palliat Care, V18, P190, DOI 10.4103/0973-1075.105689
  20. Jensen SB, 2014, J ORAL PATHOL MED, V43, P81, DOI 10.1111/jop.12135
  21. Jensen SB, 2013, SUPPORT CARE CANCER, V21, P3223, DOI 10.1007/s00520-013-1884-6
  22. Jones JA, 2006, SUPPORT CARE CANCER, V14, P505, DOI 10.1007/s00520-006-0055-4
  23. Kawano Y, 2016, CHEM PHARM BULL, V64, P1659, DOI 10.1248/cpb.c16-00217
  24. Kazemian A, 2009, EUR J CANCER CARE, V18, P174, DOI 10.1111/j.1365-2354.2008.00943.x
  25. Keefe DM, 2007, CANCER-AM CANCER SOC, V109, P820, DOI 10.1002/cncr.22484
  26. KIM JH, 1985, INT J TISSUE REACT, V7, P215
  27. KIM JH, 1986, AM J CLIN ONCOL-CANC, V9, P132, DOI 10.1097/00000421-198604000-00006
  28. Kwon Y, 2016, ONCOTARGETS THER, V9, P2007, DOI 10.2147/OTT.S96899
  29. Lalla RV, 2014, ORAL ONCOL, V50, P1098, DOI 10.1016/j.oraloncology.2014.08.001
  30. Lalla RV, 2014, CANCER-AM CANCER SOC, V120, P1453, DOI 10.1002/cncr.28592
  31. Lalla RV, 2012, SUPPORT CARE CANCER, V20, P1797, DOI 10.1007/s00520-011-1277-7
  32. Lalla RV, 2010, SUPPORT CARE CANCER, V18, P95, DOI 10.1007/s00520-009-0635-1
  33. LEVER SA, 1987, DRUG INTEL CLIN PHAR, V21, P359, DOI 10.1177/106002808702100412
  34. Logan RM, 2007, ORAL ONCOL, V43, P395, DOI 10.1016/j.oraloncology.2006.04.011
  35. Mallick S, 2016, EUR ARCH OTO-RHINO-L, V273, P2285, DOI 10.1007/s00405-015-3694-6
  36. Murphy BA, 2009, J PAIN SYMPTOM MANAG, V38, P522, DOI 10.1016/j.jpainsymman.2008.12.004
  37. Nicolatou-Galitis O, 2013, SUPPORT CARE CANCER, V21, P3179, DOI 10.1007/s00520-013-1847-y
  38. Nicolatou-Galitis O, 2013, SUPPORT CARE CANCER, V21, P357, DOI 10.1007/s00520-012-1613-6
  39. NIH, 2011, SAF EFF STUD BENZ OR
  40. Nomura M, 2013, ANN ONCOL, V24, P1062, DOI 10.1093/annonc/mds584
  41. Ong ZY, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-22
  42. PRADA A, 1985, INT J TISSUE REACT, V7, P237
  43. PRADA A, 1987, INT J TISSUE REACT, V9, P115
  44. Pusztai L, 2004, CYTOKINE, V25, P94, DOI 10.1016/j.cyto.2003.10.004
  45. Putwatana P, 2009, CANCER NURS, V32, P82, DOI 10.1097/01.NCC.0000343362.68129.ed
  46. Ranna V, 2019, SUPPORT CARE CANC
  47. Rastogi M, 2017, SUPPORT CARE CANCER, V25, P1439, DOI 10.1007/s00520-016-3548-9
  48. Roopashri G, 2011, CONTEMP CLIN DENT, V2, P8, DOI 10.4103/0976-237X.79292
  49. Rubenstein EB, 2004, CANCER-AM CANCER SOC, V100, P2026, DOI 10.1002/cncr.20163
  50. SAMARANAYAKE LP, 1988, CLIN RADIOL, V39, P291, DOI 10.1016/S0009-9260(88)80538-5
  51. SCHUBERT MM, 1987, INT J TISSUE REACT, V9, P99
  52. Sheibani KM, 2015, ASIA-PAC J CLIN ONCO, V11, P22, DOI 10.1111/ajco.12288
  53. Somerfield MR, 2000, CLASS PAP CURR COMME, V4, P881
  54. SONIS S T, 1985, Journal of Oral Medicine, V40, P67
  55. Sonis Stephen T, 2004, J Support Oncol, V2, P3
  56. Sultani Masooma, 2012, Chemother Res Pract, V2012, P490804, DOI 10.1155/2012/490804
  57. Sun WH, 2000, J PHARMACOL EXP THER, V295, P447
  58. Veness M J, 2006, Australas Radiol, V50, P468, DOI 10.1111/j.1440-1673.2006.01628.x
  59. Vera-Llonch M, 2007, SUPPORT CARE CANCER, V15, P491, DOI 10.1007/s00520-006-0176-9
  60. Yasuda Takashi, 2012, J Oral Maxillofac Res, V2, pe3, DOI 10.5037/jomr.2011.2403
  61. Yokota T, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3295-4

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - ODS/03